A pilot assessment was conducted to test the ﬁrst version of the HTA Core Model and the draft Guidelines for Rapid relative effectiveness assessment (REA) of pharmaceuticals, as well as the capacity for international collaboration required to produce an assessment. The aim of the present study was to describe and analyze the lessons learned from the pilot project based on input from three different perspectives: the assessors, the users (HTA organizations) and the marketing authorization holder (MAH). This article does not address the scientiﬁc quality of the pilot report.
|Numero di pagine
|International Journal of Technology Assessment in Health Care
|Stato di pubblicazione
|Pubblicato - 2014